Form 4: Ocular Therapeutix Executive Sells Shares to Cover Tax Obligations

Pravin Dugel, Executive Chairman, President, and CEO of Ocular Therapeutix, sold shares to cover tax obligations related to vesting restricted stock units.

Summary

• Pravin Dugel, Executive Chairman, President, and CEO of Ocular Therapeutix, sold 21,626 shares of common stock on May 23, 2024.
• The sale was executed at a weighted average price of $5.79 per share, with individual transactions ranging from $5.74 to $5.81.
• The sale was conducted automatically under a pre-arranged plan adopted on February 21, 2024, to cover tax withholding obligations related to the vesting of restricted stock units on May 22, 2024.
• Following the transaction, Dugel still beneficially owns 833,353 shares of Ocular Therapeutix common stock.

Sentiment

Score: 5

Explanation: This Form 4 filing represents a routine transaction related to tax obligations. It doesn't indicate a positive or negative sentiment towards the company's prospects.

Future Outlook

There is no future outlook provided in this document.

Management Comments

• The sales do not represent a discretionary trade by the reporting person.

Industry Context

This is a routine transaction related to executive compensation and tax obligations, common in publicly traded companies. It doesn't necessarily reflect a change in the executive's confidence in the company.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across the pharmaceutical and biotech industries.
• Companies like Regeneron, Amgen, and Vertex Pharmaceuticals often see similar filings from their executives related to RSU vesting and tax payments.
• The number of shares sold and the percentage of total holdings are within typical ranges for such transactions.

Stakeholder Impact

• The sale of shares by a company executive could have a minor impact on shareholder sentiment, but is unlikely to have a significant long-term effect given the reason for the sale.

Key Dates